I et længerevarende, 26- ugers placebo- kontrolleret forsøg var forekomsten af EPS 19% for aripiprazol- behandlede patienter og 13, 1% for placebo- behandlede patienter.
In a long term 26-week placebo-controlled trial, the incidence of EPS was 19% for aripiprazole-treated patients and 13.1% for placebo-treated patients.